Navigation Links
Atrium generates strong growth during the second quarter
Date:8/7/2008

Significant increase in revenues and net earnings from continued

operations of 165% and 157% respectively

All amounts are in US dollars.

QUEBEC CITY, Aug. 7 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries, disclosed today its financial results for the second quarter of 2008.

Quarterly highlights:

- Sale of AI&SC Division completed, allowing to focus activities in the

promising health and nutrition sector;

- Strong organic growth in sales and earnings;

- Strong growth also contributed by the two recent acquisitions, Mucos

and MCO. Integrations are proceeding smoothly;

- Strong financial position and well positioned to pursue the acquisition

strategy;

- Favorable short-term outlook.

During the quarter ended June 30, 2008, Atrium recorded revenues from continuing operations of $74.5 million, which represents an increase of 165% compared to revenues of $28.2 million for the corresponding quarter in 2007. Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the second quarter of 2008 increased by 128% to $18.2 million compared to $8.0 million for the same period in 2007. For the quarter ended June 30, 2008, net earnings from continuing operations were $10.7 million compared to $4.2 million for the same period in 2007, an increase of 157%.

The Company's total net earnings were $43.9 million compared to net earnings of $6.6 million for the corresponding period in 2007. For the second quarter of 2008, net earnings per share on a diluted basis rose to $1.33 per share, compared to $0.20 per share for the same period in 2007. Net earnings and net earnings per share in 2008 include a net gain of $30.9 million on the sale of the AI&SC Division.

For the
'/>"/>

SOURCE Atrium Innovations Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Atrium Innovations Announces Management Changes
2. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
3. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
4. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
5. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
6. Atrium shows a strong financial performance for its first quarter
7. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
8. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
9. Atrium Innovations to Present at Upcoming 28th Annual Canaccord Adams Global Growth Conference
10. Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
11. Imaging Diagnostic Systems Generates Cash From Building Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
... has closed a public offering of three million ... million for general corporate purposes. , ,The company announced ... $3.75 per share, marketed to institutional investors following a ... Exchange Commission . , ,Sonic Foundry, which develops a ...
... , a Grand Rapids-based provider of data bandwidth capacity, will ... in metropolitan Milwaukee. , ,The company, which serves Midwestern enterprise ... 31 of this year. , ,US Signal's network deployment ... Milwaukee and powered by the Cisco optical platform. ...
... Madison, Wis. - Third Wave Technologies, Inc ., ... to the U.S. Food and Drug Administration for approval of ... test product, which Third Wave calls InPlex, is a genotyping ... to aid in newborn screening and in diagnostic testing in ...
Cached Biology Technology:
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... of choice when it comes to the types of fat cells in ... it. The danger in white fat cells, along with the increased risk ... fat. Visceral fat is the build-up of fat around the organs in ... fat appears to be our friend and white fat our foe. ...
... FL (May 6, 2012) There may be new ... medicine injected directly into the eyes fails to cause ... called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle ... with the fast-progressive form of macular degeneration, they are ...
... in German . Halle/Saale. In order to ... These differ in part considerably from the propagation strategies of ... Knapp of the Helmholtz Centre for Environmental Research (UFZ) reached ... of the scientific journal Ecology Letters . "These results ...
Cached Biology News:A new candidate pathway for treating visceral obesity 2First oral agent to quell invasive macular degeneration, restore lost vision 2First oral agent to quell invasive macular degeneration, restore lost vision 3Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... offers single pass sequencing of plasmids ... fueled by our high performance sequencing ... Phred20 bases per day. The key ... sequencing customers are rapid turnaround, high ...
... Agencourt offers a high quality whole genome ... while reducing costs allow even the smallest ... endeavors. The key features which set our ... unique library construction strategies, proprietary assembly software, ...
Biology Products: